News Releases

Date Title and Summary
Toggle Summary electroCore Provides Business Update and Select First Quarter 2020 Guidance
BASKING RIDGE, N.J. , April 17, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020.
Toggle Summary electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in the U.K.
ITP program reimbursing for gammaCore™ extended to Sept. 30, 2020 BASKING RIDGE, N.J. , April 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service ( NHS ) has exercised its option to
Toggle Summary electroCore Submits Emergency Use Authorization Application to Allow the Study and Use of gammaCore nVNS Therapy to Treat Respiratory Symptoms Associated with COVID-19
BASKING RIDGE, N.J. , April 02, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) to facilitate
Toggle Summary electroCore Announces 510(k) Clearance of gammaCore™ Label Expansion into Migraine Prevention
Approval makes novel non-invasive vagus nerve stimulation therapy available for prevention as well as acute treatment of migraines in adults BASKING RIDGE, N.J. , March 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced
Toggle Summary electroCore Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital
BASKING RIDGE, N.J. , March 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into a common stock purchase agreement of up to $25 million with Lincoln Park Capital Fund, LLC (“Lincoln Park”), a
Toggle Summary electroCore Announces Changes to its Board of Directors
John Gandolfo, Tom Patton and Peter Cuneo to join the Board, adding significant medical technology operational, financial and turn-around experience BASKING RIDGE, N.J. , March 26, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today
Toggle Summary electroCore Announces Fourth Quarter and Full Year 2019 Financial Results
Continued growth in VA and U.K. Channels Company to host conference call and webcast today, March 23, 2020 at 4:45 pm  ET BASKING RIDGE, N.J. , March 23, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced fourth quarter 2019
Toggle Summary electroCore to Announce Fourth Quarter and Year Ended December 31, 2019 Financial Results on Monday, March 23
Conference Call to be Held at 4:45pm Eastern Time BASKING RIDGE, N.J. , March 19, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the fourth quarter and year ended December 31, 2019
Toggle Summary electroCore, Inc. Announces Rebate Agreement with Ascent Health Services for gammaCore Preferred Brand Coverage on all Express Scripts Standard National Formularies
Agreement opens reimbursement pathway for thousands of patients with migraine and cluster headache BASKING RIDGE, N.J. , Jan. 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Ascent Health Services on behalf of
Toggle Summary electroCore Provides Business Update and Select Financial Guidance
BASKING RIDGE, N.J. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on its commercial operations, clinical development programs, and introduced select preliminary unaudited guidance for the fourth